CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...
Phase 2
Madrid, Spain and 83 other locations
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer...
Phase 2
Madrid, Spain and 49 other locations
Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer....
Phase 1
Madrid, Spain and 12 other locations
to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...
Phase 3
Madrid, Spain and 54 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Madrid, Spain and 209 other locations
locally advanced or metastatic disease.In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors...
Phase 1
Madrid, Spain and 21 other locations
the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...
Phase 1, Phase 2
Madrid, Spain and 30 other locations
over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...
Phase 1
Madrid, Spain and 38 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
Madrid, Spain and 123 other locations
in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...
Phase 1, Phase 2
Madrid, Spain and 48 other locations
Clinical trials
Research sites
Resources
Legal